Greater Manchester Medicines Management Group

Greater Manchester Clinical Standards Board

NHS

GMMMG Consultations

 

On this page you will find proposed changes that are currently going through the GMMMG approval process. This will include consultations on proposed RAG status, updated Formulary Chapters, Pathways or other GMMMG Guidance. You will be able to comment on current proposals via the links in the table below.

Title

Information

Feedback

End date

66

PaGDSG Shared Care Protocol for First generation (Typical) antipsychotic depots in adults

On behalf of the GMMMG Pathways and Guidelines Development Subgroup, a Greater Manchester-wide Shared Care Protocol for First generation (Typical) antipsychotic depots in adults is in development. We now seek comments on this draft. This consultation period is open until 5pm Tuesday 22nd October.

Feedback Form

5pm Tuesday
22nd October 2019

65

PaGDSG Shared Care Protocol for Riluzole for ALS

On behalf of the GMMMG Pathways and Guidelines Development Subgroup, a Greater Manchester-wide Shared Care Protocol for Riluzole for ALS is in development. We now seek comments on this draft. This consultation period is open until 5pm Tuesday 22nd October.

Feedback Form

5pm Tuesday
22nd October 2019

64

FMESG proposed actions for August 2019

The following FMESG actions for August 2019 have been proposed and will be sent to CSB for support. We now seek comments on these proposals.  This consultation is open until 5pm on Monday 21st October 2019

Feedback Form

5pm Monday
21st October 2019

63

FMESG proposed actions for July 2019

The following FMESG actions for July 2019 have been proposed and will be sent to CSB for support. We now seek comments on these proposals.  This consultation is open until 5pm on Monday 23rd September 2019

Feedback Form

5pm Monday
23rd September 2019

62

On behalf of the GMMMG HCD Groups, a Greater Manchester-wide commissioning statement for Bezolotoxumab  (Zinplava®) for the Prevention of Recurrence of Clostridium Difficile Infection in Adults at High Risk of Recurrence is in development. 

The statement has been developed in line with the information currently available and aims to prevent variation in prescribing of this agent across GM. Updated guidance from PHE is pending and the planned NICE TA has been suspended as the manufacturer failed to submit the necessary information. GMMMG feel that the place in therapy for this agent is unclear and so seek the views of the GM health economy and population. There is no proposed financial and commissioning impact as this agent is not recommended for prescribing, however additional information is included within the statement.

We now seek comments on this draft. This consultation period is open until 5pm on Monday 23rd of September.

Feedback Form

5pm Monday
23rd September 2019

61

On behalf of the GMMMG HCD Groups, a Greater Manchester-wide commissioning statement for Fidaxomicin (Dificlir®) for the Treatment of Clostridium Difficile Infection is in development.

A formal commissioning policy is required as fidaxomicin was added to the PBR Tariff Excluded Drugs List as a CCG commissioned drug from the 1st April 2019. Fidaxomicin is currently included on the GMMMG RAG list as a green plus drug, on the advice of microbiology. There is no change in the route of access proposed by this statement; it is the payment mechanism which has changed.

We now seek comments on this draft. This consultation period is open until 5pm on Monday 23rd of September.

Feedback Form

5pm Monday
23rd September 2019

<< Back

Line

TERMS AND CONDITIONS    |    CONTACT US    |    ABOUT US    |    ARCHIVE

RSS Feed
 
spacer